Lupin Launches Triple-Combination Inhaler For COPD; Shares Up 0.21%

Mumbai, October 6: Lupin Limited has launched Formoflo-G® MDI in India, a fixed-dose triple-combination metered-dose inhaler for the long-term management of chronic obstructive pulmonary disease (COPD). 

According to the company’s exchange disclosure, the product was launched following approval from the Drug Controller General of India (DCGI). Lupin describes Formoflo-G® MDI as the world’s first fixed-dose triple-combination MDI for COPD management. 

The inhaler combines Glycopyrronium Bromide, Formoterol Fumarate and Fluticasone Propionate in a single formulation. It is available as a twice-daily, single-strength fixed dose. 

Stock Market Snapshot 

The Lupin share price stood at ₹2,015.30 as of 11:32:46 AM IST on October 6, 2026, according to the market data. 

The stock was up ₹4.30, or 0.21%, at the time. Shares moved higher through the morning after opening around the ₹2,010 level and briefly crossed ₹2,020. 

The Lupin share price movement came as the company announced the launch of Formoflo-G® MDI in India’s respiratory medicines market. 

Formoflo-G Combines Three Established Therapies 

Formoflo-G® MDI brings three active ingredients together in a single inhaler, combining a long-acting muscarinic antagonist, a long-acting beta-agonist and an inhaled corticosteroid. 

Lupin said the product is intended for the long-term management and treatment of moderate to severe COPD. The company cited data indicating that more than 55 million people in India live with COPD, highlighting the size of the respiratory disease burden in the country. 

The launch gives patients and healthcare professionals another fixed-dose option for COPD management, subject to the approved product indications. 

Lupin Strengthens Its Respiratory Portfolio 

Nilesh Gupta, Managing Director of Lupin, said the launch is aimed at addressing unmet needs in respiratory care by combining innovation with accessibility. 

Rajeev Sibal, President, India Region Formulations, said Formoflo-G® MDI brings three established therapies together in one inhaler and adds to Lupin’s respiratory portfolio. 

The company said it ranked second in India’s respiratory therapy segment, based on IQVIA MAT March 2026 data. The latest product launch further strengthens its presence in the segment. 

Lupin Expands Access To COPD Treatment 

Lupin is a global pharmaceutical company with operations across India, the US, other developed markets and emerging markets. Its portfolio includes generics, complex generics, specialty medicines and biosimilars. 

The company has a significant presence in respiratory therapies and operates manufacturing facilities and research centres across multiple markets. The Formoflo-G® MDI launch adds another differentiated respiratory product to its India portfolio following regulatory approval. 

Conclusion 

Lupin’s launch of Formoflo-G® MDI expands its respiratory portfolio with a three-drug fixed-dose inhaler for COPD management in India. The product combines Glycopyrronium Bromide, Formoterol Fumarate and Fluticasone Propionate, while the Lupin share price was up 0.21% at ₹2,015.30 as of 11:32:46 AM IST on October 6, 2026.  

Source: 

• https://www.nseindia.com/get-quote/equity/LUPIN/Lupin-Limited    
• https://nsearchives.nseindia.com/corporate/Lupin2_06102026093541_SELetterpressrelease.pdf